Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

AnaptysBio Q3 EPS $0.52 Beats $(1.42) Estimate, Sales $76.320M Beat $15.811M Estimate

Author: Benzinga Newsdesk | November 04, 2025 04:38pm
AnaptysBio (NASDAQ:ANAB) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $(1.42) by 136.65 percent. This is a 145.61 percent increase over losses of $(1.14) per share from the same period last year. The company reported quarterly sales of $76.320 million which beat the analyst consensus estimate of $15.811 million by 382.69 percent. This is a 154.26 percent increase over sales of $30.017 million the same period last year.

Posted In: ANAB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist